The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Flatiron Health

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
 
Gregory J. Riely
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Christine Marie Lovly
Honoraria - ARIAD; Cepheid; Foundation Medicine; Novartis; Pfizer; Takeda
Consulting or Advisory Role - ARIAD; Cepheid; Foundation Medicine; Novartis; Pfizer; Takeda
Research Funding - Novartis; Xcovery
Travel, Accommodations, Expenses - ARIAD; Cepheid; Foundation Medicine; Novartis; Pfizer; Takeda
 
Carlo GM Messina
Employment - Roche
Leadership - Roche
Stock and Other Ownership Interests - Roche
 
Stefanie Bienert
Employment - Roche; Roche (I)
 
Kimberly Alexander
Employment - Roche
Travel, Accommodations, Expenses - Roche
 
William Pao
Employment - Roche
Leadership - Roche
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - MolecularMD; MyCancerGenome
 
Shrujal Baxi
No Relationships to Disclose
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech